This discovery could pave the way for the relatively rapid development of a vaccine against Chlamydia.
"Now that we know how the body defends itself against the Chlamydia bacteria, we can develop a vaccine that optimises that defence. We have a basic understanding of how the vaccine could work, but some work remains to be done. We believe that it will take a few years before the vaccine becomes a reality," says researcher Ellen Marks, the author of the thesis.
The body defends itself against infections with a type of white cell called the T lymphocyte. When these blood cells take on the bacteria, they trigger an inflammation that can damage tissue, so there are also other similar blood cells whose main task is to reduce the inflammation and protect tissue. Ellen Marks and her colleagues are the first research team to discover that these anti-inflammatory forces predominate in the lower parts of the female genital tract, mainly mediated by a hormone called IL-10, which is highly protective against tissue damage.
"The result is that the T lymphocytes that could fight Chlamydia are not concentrated in the lower vagina, and the infection can move up towards the womb and fallopian tubes relatively unhindered," says Ellen Marks.
The research team already has a concept of how a vaccine based on this new understanding could work, and they have also tested it on mice.
"The method of administration is an important remaining issue. Previous research has shown that injections don't work, and so the vaccine will probably need to be given either as a nasal spray or in the form of a cream applied into the vagina," says Ellen Marks.
This research is being done at MIVAC (the Mucosal Immunology and Vaccine Center) - the Sahlgrenska Academy's strategic research centre. Researchers at the centre are developing novel methods of treating diseases that affect our mucous membranes.FACTS ABOUT CHLAMYDIA
Title of thesis: Genital tract CD4+ T cells for vaccination and protection against Chlamydia trachomatis
The thesis has been defended.
You can read the complete thesis here: http://hdl.handle.net/2077/21075
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
19.03.2018 | Physics and Astronomy
19.03.2018 | Materials Sciences
19.03.2018 | Event News